Inaqovi (Decitabine, Cedazuridine)

Decitabine is a nucleoside analog that incorporates into DNA and irreversibly inhibits DNA methyltransferase enzymes. This causes hypomethylation of genomic DNA, re‑activating silenced tumor‑suppressor genes and leading to differentiation or apoptosis of malignant hematopoietic cells.

The prescribed dose of Inaqovi is determined by the treating physician based on the patient’s disease characteristics, organ function, and prior therapy. Each tablet contains a fixed combination of 35 mg decitabine and 100 mg cedazuridine and is taken orally on the schedule recommended by the clinician.

Safety of Inaqovi in pregnancy has not been established; animal data suggest potential teratogenic effects, so it should be avoided in pregnant women. Breastfeeding is not recommended because the drug may be excreted in milk and could affect the infant. Consultation with a specialist is essential.

To order Inaqovi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

The primary alternative is intravenous decitabine or the hypomethylating agent azacitidine. Inaqovi combines decitabine with cedazuridine to enable oral administration, offering comparable efficacy while avoiding infusion‑related logistics. Azacitidine is also available orally but uses a different formulation; choice depends on patient preference, tolerability and clinical judgment.

Store Inaqovi at ambient temperature below 25 °C in its original packaging. Protect the tablets from moisture and direct light. Do not refrigerate or freeze. Keep out of reach of children and handle with clean, dry hands.

Inaqovi is taken as an oral tablet with water, usually on a designated day of each treatment cycle as directed by the prescriber. Food does not significantly affect absorption, but patients should follow the exact schedule provided and avoid missing doses without medical advice.

The most serious risks include severe myelosuppression leading to infections such as febrile neutropenia, life‑threatening bleeding due to thrombocytopenia, and pulmonary toxicity such as interstitial pneumonitis. Prompt medical attention is required if signs of infection, unexplained fever, or respiratory symptoms develop.

Inaqovi should not be used by individuals with known hypersensitivity to decitabine, cedazuridine, or any tablet excipients. It is contraindicated in pregnant or breastfeeding women, patients with severe hepatic impairment, and those with uncontrolled active infections. Clinicians must evaluate each patient’s medical history before initiating therapy.